Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Equity Average (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Equity Average for 13 consecutive years, with $95.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Average fell 20.5% year-over-year to $95.7 million, compared with a TTM value of $95.7 million through Dec 2025, down 20.5%, and an annual FY2025 reading of $96.8 million, down 43.99% over the prior year.
  • Equity Average was $95.7 million for Q4 2025 at Enanta Pharmaceuticals, up from $72.0 million in the prior quarter.
  • Across five years, Equity Average topped out at $444.0 million in Q1 2021 and bottomed at $72.0 million in Q3 2025.
  • Average Equity Average over 5 years is $247.7 million, with a median of $240.4 million recorded in 2023.
  • The sharpest move saw Equity Average fell 8.29% in 2021, then tumbled 48.15% in 2025.
  • Year by year, Equity Average stood at $391.9 million in 2021, then dropped by 20.62% to $311.1 million in 2022, then plummeted by 34.32% to $204.3 million in 2023, then crashed by 41.11% to $120.3 million in 2024, then decreased by 20.5% to $95.7 million in 2025.
  • Business Quant data shows Equity Average for ENTA at $95.7 million in Q4 2025, $72.0 million in Q3 2025, and $86.4 million in Q2 2025.